68 results about "Colorectal Tumors" patented technology

Disclosed is a method for determining the presence or absence of a colorectal tumor, specifically colorectal cancer or colorectal adenoma, with high sensitivity and high specificity by employing the methylation of DNA as a measure. Also disclosed is a kit for carrying out the method. Specifically, measurement is made on the degree of methylation of one or more CpG sequences contained in the region lying between positions -477 to -747, more preferably a CGCG sequence contained in the region lying between positions -688 to -691, in TWIST1 gene (Homo sapiens twist homolog 1; Drosophila gene) located on the genome sequence of a test cell.

In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.

The invention relates to primers and probes used for human colorectal tumor specific methylation detection and application thereof and a kit used for human colorectal tumor specific methylation detection. According to the technical scheme, for a promoter high GC area of a human genome SFRP2 gene, a pair of the methylation specific Real-time PCR primers and the corresponding probes are designed. The primers and the probes are adopted for conducting Real-time PCR detection on a to-be-detected sample subjected to sulfite transformation, according to an amplification result, whether or not the to-be-detected sample is an SFRP2 gene methylation sample is judged, and then whether or not the to-be-detected sample is a colorectal tumor sample is judged. The primers and the probes used for human colorectal tumor specific methylation detection and the application thereof and the kit used for human colorectal tumor specific methylation detection have the beneficial effects that the specificity ishigh, wherein a colorectal tumor specific marker is adopted, and the specificity of colorectal tumor detection is up to 92.3%; the sensitivity is high, wherein the total sensitivity of colorectal tumor detection is 76.3%, specifically, the sensitivity of colorectal cancer detection is 84.6%, and the sensitivity of precancerous lesion detection is 58.3%.

The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal tumors.

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor assoicated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.

The invention relates to application of miR-24-1-5p to colorectal tumor. An expression condition of the miR-24-1-5p in a colorectal tumor tissue and five types of colorectal tumor cell lines is detected by fluorescent quantitative PCR (Polymerase Chain Reaction) and a result finds out that the expression of the miR-24-1-5p in the colorectal tumor tissue and cells is obviously regulated downwards and the miR-24-1-5p plays an important regulation and control role in occurring and development processes of the colorectal tumor. By constructing an miR-24-1-5p overexpression carrier, a colorectal tumor cell Caco2 and HCT-116 cells are transfected, and MTT (Methyl Thiazolyl Tetrazolium), cell scratch, Transwell and plate cloning experiments are used for researching influences of the miR-24-1-5p on proliferation and migration of the colorectal tumor cells; results show that the miR-24-1-5p can be used for remarkably inhibiting the proliferation and the migration of the colorectal tumor cells and can be used for a biological preparation for treating the colorectal tumor.

The invention discloses a tumor marker related to colorectal cancer and application. The tumor marker is lncRNA (long noncoding RNA) and is located on the seventeenth chromosome of chr17: 47785696-47797422, a nucleotide sequence of the lncRNA is shown in SEQ ID NO.1 is named as lncRNA-KAT7. According to the lncRNA-KAT7 sequence, specific real-time fluorescent quantitative PCR primer can be designed and synthesized to be used for preparing preparation for colorectal cancer diagnosis or treating effect prediction. By means of the real-time fluorescent quantitative PCR preparation, expression level of lncRNA-KAT7 is detected in colorectal cancer clinical case specimen, expression of the lncRNA-KAT7 in the colorectal cancer is found to be obviously reduced, the lncRNA-KAT7 has obvious statistic significance (p<0.05), and low expression of the lncRNA-KAT7 in the colorectal cancer is closely related to colorectal tumor differentiation, T staging, invasion and metastasis. The result shows that the lncRNA-KAT7 can serve as the tumor marker of the colorectal cancer and can be used for preparing preparation or kits applied to auxiliary diagnosis, treating effect prediction and prognosis of the colorectal cancer.

The invention provides convenient food for conditioning colorectal neoplasms. L-glutamine acts as the main material of the convenient food, and according to the constitutive characters of patients suffering from colorectal neoplasms, the convenient food is prepared by the steps of reasonably and specifically blending food and drug herbal extracts, such as dendrobe, semen coicis, jerusalem artichoke, Chinese yam, dandelion, hawthorn, ficus carica L, honeysuckle, endothelium corneum gigeriae galli, hericium erinaceus, sea-buckthorn, fingered citron, medlar, semen raphani, pawpaw, apricot kernels, raspberry, portulaca oleracea and fructus amomi by utilizing the essence of the theory of traditional Chinese medicine, extracting the herbal extracts by a biological enzymolysis or prehydrolysis SBE technique, and then adding prebiotics, ammonia acids, oligopeptide, vitamins and minerals and mixing so as to prepare the convenient food. The convenient food prepared according to the formula provided by the invention is easy to dissolve, can be absorbed and utilized rapidly, can improve the nutritional condition of the patients suffering from colorectal neoplasms, can be used for assisting in improving the organism immunity by the effect of the bioactive components in the food and drug herbal extracts, plays roles of inhibiting and resisting cancers, and is suitable for patients suffering from colorectal neoplasms or patients which suffering from cancers and receiving radiotherapy or chemotherapy to eat, and therefore, the convenient food has the unique advantage of integrating the three efficacies of dietary therapy, prevention and conditioning.

Disclosed is a method for detecting colorectal tumor, particularly advanced adenoma and early cancer, in which a component contained in feces is employed as a measure. Specifically disclosed is a colorectal tumor detection method using a marker gene, which comprises the steps of (A) extracting RNA from feces collected from a subject, (B) measuring the amount of RNA derived from the marker gene contained in the RNA that has been obtained in step (A), and (C) comparing the amount of the RNA derived from the marker gene which has been measured in step (B) with a threshold value that has been determined previously depending on the type of the marker gene, and which is characterized in that the marker gene is CKB (creatine kinase B) gene.

Immune context scores are calculated for stage IV colorectal tumor tissue samples using non-continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a density of human CD8+ cells in a region of interest including a tumor core to generate an immune context score. The immune context score can then be used as a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and / or treatment decisions.